Exactly, I think that is the plan; otherwise he would have taken one of them all the way. They have a lot in the pipeline they haven't done anything with, so with the income stream they will keep developing more adding to the income stream. Getting harder and harder to bring up the message board. Yahoo trying to kill it. I am moving on to ihub and stocktwits once total access is removed.
Didn't say they were selling today. I think they are building up the value of the pipeline horizontally without going through PHIII trIals. To sell the current three candidates, partner the three with one or more companr most likely one, sell the Co outright, or keep one. That won't happen until some of these PICs or PII trials end.
to be bought out. They may already have interest for the pipeline by a suitor that is asking for more data on the breath of some of the drugs. To get the minimum ask. IMHO. Shorts on RYLP are in disbelief, shocked, acting disoriented. Same behavior I've observed on other Biotech's I've owned that have been BO like TRIUS, DRTX., etc.
Nothing. Buyout still in play. Biotechs selling in am. Look to reverse. Folks want to sell go ahead. An announcement could be forthcoming anytime. Buy more if you can.
Making lots of $$$. CTIX is a spec play. I own a lot of shares but never gave too much importance on P. I'd be more concerned with the upcoming B-OM results. I may add more CTIX, maybe if BMRN gets bought out. I think the new hire will make it clearer on the path forward for CTIX's pipeinr. There are alot of self proclaimed experts on law, patent law, molecular chemistry, without giving any benefit of the doubt to Dr. Menon, Leo, USPTO, etc. Of course the board posters must be believed versus the Company experts. Just don't make any rash investing decisions based on the Prurisol ping pong match.
If CS makes a fair value assessment in the $130 -- $150 range, it shows you how inane the market has valued a lot of biotechs. Maybe the catalyst's needed to get the sector moving up again.
I think they want to move prior to any SNY offer. Source said they were about to move, but put on hold due to Brexit...now is ready to move forward somewhat prompted that BMRN is a backup plan for SNY. I can't say one way or another, do you have an authoritative source, given your strong opinion?
Source is adamant that the deal is going forward this time. Roche working with CS to make the proposal. Fair value assessment $130-$150 per share.
Seems fully priced here. CELG would probably do a partnership, which is what MDVN wants, not a BO. PFE is the more realistic player. SNY will withdraw IMO.
I would say even B is the one management needs to be advancing in this favorable antibiotic environment. The discussion P is overdone. It's an afterthought. If CTIX's can sell it for some cash great. It doesn't require a lot of expense to trial anyway. Let's move on, please!
The move for biotechs will take place well before the election. Could be starting now.
The strengh in biotechs showed what I'd call a reversal. They showed better relative strength when the stocks were intraday going down and up during the 2 day Brexit route.
What I have been saying all along. Yet was ridiculed. Even CEMP said the $$$ they have are only good to the 1st quarter of 2017, which means they have to raise this year ...right. $13 is optimistic more like $5. But the longs here continue to support the CEO who cannot get a partner, because its not worth any where near what she thinks it is worth. IMHO.
gets rejected. SNY is raising alot of $$$. MDVN is overplaying their hand. BMRN is a much better target for SNY, and I think they will make a move.